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Background: In a 1-year, randomized, open-label study in patients with moderate-to-severe
allergic (immunoglobulin E (IgE)-mediated) asthma, adding omalizumab to best standard care
(BSC) significantly improved efficacy outcomes compared with BSC alone (control). We as-
sessed the efficacy of omalizumab in the subgroup of patients with inadequately controlled se-
vere persistent allergic asthma despite high-dose inhaled corticosteroids (ICS) plus a long-
acting b2-agonist (LABA), which reflects the European Union (EU) label population.
Methods: Efficacy outcomes included annual asthma exacerbation rate, annual asthma deteri-
oration-related incident (ADRI) rate, % predicted forced expiratory volume in 1 s (FEV1),
asthma symptoms (Wasserfallen score) and quality of life (Mini Asthma Quality of Life Ques-
tionnaire (Mini-AQLQ)), which were compared in the omalizumab and control groups. Out-
comes were also determined for omalizumab-treated patients judged to have responded to
therapy (0.5-point improvement in Mini-AQLQ overall score at 27 weeks).
Results: In total, 164 patients (omalizumab, nZ 115; control, nZ 49) were receiving high-
dose ICS plus a LABA. Annual asthma exacerbation rate was significantly reduced by 59% in
the omalizumab group vs. control (1.26 vs. 3.06; P < 0.001). ADRI rate was significantly re-
duced by 40% in the omalizumab group compared with control (5.61 vs. 9.40; P < 0.05). Signif-
icant improvements were also seen in % predicted FEV1 (71% vs. 60%; P < 0.001), change from
baseline in asthma symptom scores (6.7 vs. 0.5; P < 0.05) and Mini-AQLQ overall score (1.32
vs. 0.17; P < 0.001).
In omalizumab-treated patients, 71/102 (70%) were judged to have responded to therapy. In
these Mini-AQLQ-assessed responders, exacerbation rate was reduced by 64% vs. control (1.12
vs. 3.06; P < 0.001), ADRI rate was reduced by 50% vs. control (4.71 vs. 9.40; P < 0.01). Percent
predicted FEV1 (73% vs. 60%; P < 0.001), change from baseline in asthma symptom scores1 291 2834; fax: þ44 161 291 2832.
ht.nwest.nhs.uk (R. Niven).
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1372 R. Niven et al.(8.1 vs. 0.5; P < 0.001) and Mini-AQLQ overall score (1.81 vs. 0.17; P < 0.001) were also
further significantly improved vs. control.
Conclusions: Adding omalizumab to BSC is efficacious in patients with inadequately controlled
severe persistent allergic asthma despite high-dose ICS plus a LABA (EU label population), with
further efficacy observed in patients judged to have responded to therapy which may more ac-
curately illustrate the actual benefit of omalizumab therapy in clinical practice. The naturalistic
setting of this study confirms the benefits observed in double-blind randomized clinical trials.
ª 2008 Published by Elsevier Ltd.Introduction
Asthma is the cause of a significant health, economic and
societal burden, which increases with increasing asthma
severity. Patients with severe asthma are at high risk of
asthma-related hospitalization or death,1e6 suffer signifi-
cant impairment to their quality of life (QoL),7e10 and
account for the majority of asthma-related costs incur-
red.11e14 The Global Initiative for Asthma (GINA) guidelines
2006 state that the goal of asthma treatment should be to
achieve and maintain control of symptoms for long periods
with due regard to safety, adverse effects and costs.15 The
guidelines recommend a stepwise approach to asthma con-
trol, with treatment being stepped up until control is
achieved and can be maintained. At GINA step 4, medium-
or high-dose inhaled corticosteroids (ICS) plus a long-acting
b2-agonist (LABA), plus additional controller medications
are indicated. However, even with ICS plus a LABA, asthma
remains inadequately controlled in many patients.16,17 For
patients whose asthma remains uncontrolled at this step,
GINA recommends adding anti-immunoglobulin E (IgE) treat-
ment with omalizumab or oral corticosteroids (OCS).
Add-on omalizumab, an anti-IgE antibody, has proven
efficacy in the treatment of moderate-to-severe and severe
persistent allergic (IgE-mediated) asthma, reducing the
rate of exacerbations and emergency visits for asthma,
and improving QoL.18e26 In the European Union (EU), oma-
lizumab is indicated for the treatment of inadequately con-
trolled severe persistent allergic (IgE-mediated) asthma
despite treatment with high-dose ICS plus a LABA. The effi-
cacy of omalizumab in this patient population was demon-
strated in a randomized, double-blind, placebo-controlled
study (INNOVATE).18 In the INNOVATE study, adding omali-
zumab to high-dose ICS plus a LABA significantly reduced
asthma exacerbation and total emergency visit rates and
significantly improved lung function, asthma symptoms
and QoL. Confirmatory evidence was obtained in a pooled
analysis of seven randomized controlled trials in patients
with predominately severe persistent asthma.26
In the double-blind, placebo-controlled INNOVATE study,
efficacy in omalizumab-treated patients was notably im-
proved across a range of outcome measures in patients who
were judged to have responded to therapy using the
physician’s overall assessment, a composite measure that
encompasses multiple aspects of response based on clinical
assessments, including patient interview, review of medical
notes, spirometry and symptom diaries, rescue medication
use, and peak expiratory flow.27 According to the EU label,
the response to omalizumab should be assessed by a physi-
cian after 16 weeks of therapy, and treatment continuedonly if the patient has achieved complete or a marked
improvement in asthma control.
A 1-year randomized, open-label study19 in patients with
inadequately controlled moderate-to-severe allergic (IgE-
mediated) asthma with many similarities to the INNOVATE
study18 has also been conducted, however in a naturalistic
setting. Consistent with data reported in the INNOVATE
study, omalizumab significantly reduced asthma exacerba-
tion rates, significantly improved lung function and asthma
symptoms, and was shown to be safe and well tolerated.19
The aim of this post-hoc analysis was to extend the findings
of this open-label study19 with an assessment of the
effectiveness of omalizumab in a subgroup of patients
with inadequately controlled severe persistent allergic
(IgE-mediated) asthma despite receiving high-dose ICS
plus a LABA. This subgroup corresponds to the highly
targeted EU label patient population in which health-
economic analyses have shown omalizumab to be cost-
effective.28,29 In addition, efficacy was assessed in patients
judged to have responded to omalizumab therapy, reflect-
ing the EU label. Targeting patients in whom benefits are
apparent will most closely reflect the benefits that might
be expected when omalizumab is used in accordance with
the EU label, particularly when non-responders are
excluded.Methods
Study design
This post-hoc subgroup analysis was conducted on efficacy
results of a large, 1-year, randomized, open-label, parallel-
group study conducted at 49 centers in five European
countries (France, nZ 10; Germany, nZ 9; Spain, nZ 7;
Switzerland, nZ 3; United Kingdom, nZ 20).19 Further de-
tails of the original study have been reported previously.19
Briefly, patients were randomized (2:1) to receive best
standard care (BSC) with or without subcutaneous omalizu-
mab for 12 months. BSC was defined by the National Heart,
Lung and Blood Institute (NHLBI) guidelines.30 Patients
were using medium- or high-dose ICS with or without
a LABA. Use of salbutamol pressurized metered dose inhaler
as rescue medication was permitted throughout the study.
Omalizumab was administered every 2 or 4 weeks based
on baseline total IgE and bodyweight using a dosing table.
Patients had inadequately controlled asthma, defined as
1 emergency room visit or hospitalization and 1 addi-
tional course of OCS because of asthma in the previous
year.
Omalizumab in severe persistent allergic asthma 1373The subgroup analysis reported here included only pa-
tients with inadequately controlled severe persistent aller-
gic (IgE-mediated) asthma who were receiving high-dose ICS
(>1000 mg/day beclometasone equivalent) plus a LABA.
The study was performed in accordance with good
clinical practice and the latest amendments to the Decla-
ration of Helsinki, the protocol having been approved by
independent ethics committees/institutional review boards
for each center.
Efficacy assessments
Efficacy outcomes were evaluated for control patients and
omalizumab-treated patients. Additionally, in order to
reflect the EU label, outcomes were evaluated in those
omalizumab-treated patients who were considered to have
responded to therapy. A previous analysis has identified the
physician’s overall assessment as the most reliable method
of evaluating response to omalizumab therapy,27 but among
other measures of asthma control assessed in the same
study, 0.5-point improvement in the 32-item Asthma
Quality of Life Questionnaire (AQLQ) showed similar prop-
erties27 to the physician’s overall assessment in its utility
in evaluating response. As the physician’s overall assess-
ment was not an outcome measured in the original study,19
0.5-point improvement in the Mini Asthma Quality of Life
Questionnaire (Mini-AQLQ)31 overall score was used as
a measure to identify responders. The 27-week assessment
was the first assessment performed after 16 weeks of ther-
apy, which is the time specified for evaluating response to
omalizumab treatment in the EU label. Thus, in this analy-
sis, responders were defined as achieving 0.5-point im-
provement in the Mini-AQLQ overall score at 27 weeks
(further details of QoL assessments are provided below).
Efficacy variables assessed in this subgroup analysis were
the annual rate of clinically significant asthma exacerbations
(asthma worsening requiring treatment with systemic corti-
costeroids) and the annual rate of asthma deterioration-
related incidents (ADRIs) (defined as 1 of the following
events due to asthma: course of systemic corticosteroids or
antibiotics for 2 days, 2 missed school/work days (or
significantly reduced performance for non-working adult
patients, as judged by the patient), unscheduled physician
visit, or hospitalization/emergency room visit).32
Other efficacy variables assessed were lung function
analyzed as percentage of predicted forced expiratory
volume in 1 s (FEV1) (% predicted FEV1) and change in abso-
lute FEV1 at 1 year, the Wasserfallen asthma symptom
score33 and QoL (Mini-AQLQ).31 The Mini-AQLQ comprises
15 questions on symptoms (five items), activity limitations
(four items), emotional function (three items) and environ-
mental stimuli (three items). Mini-AQLQ overall and individ-
ual domain scores were recorded. In addition, the
percentage of patients with clinically meaningful (0.5),
moderate (1.0-point) and large (1.5) improvements in
Mini-AQLQ overall score at 52 weeks was calculated.Statistical analysis
For the rate of exacerbations and ADRIs, an imputation
method was applied to account for patients who werewithdrawn prematurely from the study. Between-group
differences were analyzed using Poisson regression. The
effect of add-on therapy with omalizumab on lung function
parameters (% predicted FEV1) and change from baseline in
symptom scores were analyzed using an analysis of variance
(ANOVA) model. Between-group effects on Mini-AQLQ
scores were assessed using an analysis of covariance (AN-
COVA) model and the percentage of patients with 0.5
and 1.5-point improvements in overall Mini-AQLQ scores
was compared using the Fisher exact permutation test.
Results
Baseline demographics and clinical characteristics
Of the 312 patients (omalizumab, nZ 206; control,
nZ 106) included in the original study,19 164 patients
(omalizumab, nZ 115; control, nZ 49) were receiving
high-dose ICS plus a LABA and were included in this analy-
sis. Patients’ asthma was inadequately controlled. All oma-
lizumab-treated patients and all but one of the control
patients had taken courses of OCS in the previous year. In
addition, 105 (91.3%) omalizumab-treated patients and 46
(93.9%) control patients had attended an emergency room
and 54 (47%) omalizumab-treated patients and 23 (46.9%)
control patients had been hospitalized in the previous
year. Other baseline demographic and clinical characteris-
tics of the omalizumab and control (BSC alone) groups
were also similar and are shown in Table 1. All patients
were at step 4 of GINA 2002 treatment guidelines. Despite
receiving high-dose ICS plus a LABA, and additional control-
ler medication in many cases, healthcare utilization, OCS
use and days of work/school missed in the past year were
high in both treatment groups (Table 1).
Exacerbation rates and ADRIs
The annual rate of asthma exacerbations was significantly
lower in the omalizumab group compared with control (1.26
vs. 3.06; P < 0.001, Fig. 1). The rate ratio [95% CI] for oma-
lizumab:control was 0.410 [0.288, 0.583], which equates to
a 59% reduction with omalizumab.
The annual ADRI rate was also significantly lower in the
omalizumab group than control (5.61 vs. 9.40). The rate
ratio [95% CI] for omalizumab:control was 0.597 [0.380,
0.938] (P < 0.05), which equates to a 40% reduction in
ADRIs with omalizumab. The individual events that com-
prised ADRIs during the study are summarized in Table 2.
Overall, the omalizumab group had fewer occurrences
and shorter durations of all individual ADRI events com-
pared with control although, as the study was not powered
to show differences in individual events, these were not
statistically significant.
Other outcome variables
Compared with control, patients treated with omalizumab
showed a significant improvement in % predicted FEV1
throughout the 1-year treatment period (Fig. 2). Absolute
mean [SD] FEV1 values at baseline were similar in the oma-
lizumab group (2.09 L [0.792]) and control (2.08 L [0.713]).
Table 1 Baseline demographic and clinical characteristics
Omalizumab (nZ 115) Control (nZ 49)
Age (years)
Mean (SD) 38.7 (15.52) 39.3 (13.39)
Median (range) 37.0 (12.0e73.0) 40.0 (15.0e71.0)
Sex, n (%)
Male 29 (25.2) 15 (30.6)
Female 86 (74.8) 34 (69.4)
Equivalent BDP dose, mg/day
Mean (SD) 2803.0 (1436.16) 2969.4 (1433.99)
Median (range) 2000.0 (1250.0e10000.0) 2000.0 (1500.0e8000.0)
Asthma medication, n (%)a
Anti-cholinergics 14 (12.2) 10 (20.4)
Anti-histamines 4 (3.5) 3 (6.1)
Anti-leukotrienes 40 (34.8) 20 (40.8)
Inhaled corticosteroids 115 (100) 49 (100)
Long-acting b2-agonists 112 (97.4) 49 (100)
Short-acting b2-agonists 113 (98.7) 46 (93.9)
Xanthines and xanthine derivatives 33 (28.7) 11 (22.4)
FEV1 (% of predicted), mean (SD) 65.6 (20.45) 64.1 (19.17)
Wasserfallen asthma symptom score, mean (SD) 19.1 (10.2) 17.5 (9.44)
GINA (2002) asthma severity step 4, n (%) 115 (100) 49 (100)
GINA asthma treatment step 4, n (%) 115 (100) 49 (100)
Profile of poor asthma control in last year
Patients with 1 emergency room visit, n (%) 105 (91.3) 46 (93.9)
Patients with 1 hospitalization, n (%) 54 (47.0) 23 (46.9)
Patients taking courses of OCS, n (%) 115 (100) 48 (98)
Number of OCS courses, mean (SD) 4.1 (3.49) 4.0 (4.06)
Number of days of school/work missed, mean (SD) 47.0 (76.62) 57.0 (94.79)
BDP, beclometasone dipropionate; FEV1, forced expiratory volume in 1 s; GINA, Global Initiative for Asthma; OCS, oral corticosteroids;
SD, standard deviation.
a In the 14 days prior to the baseline visit.
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and 1.93 L [0.644] in the control group (P < 0.05) represent-
ing a between-group difference of 320 mL.
At 1 year, asthma symptom score was significantly im-
proved (lower) in the omalizumab group compared with
control (12.0 vs. 17.1, P < 0.05). Analysis of change fromFigure 1 Effect of omalizumab on the rate of clinically
significant exacerbations. ***P < 0.001 vs. control.baseline in asthma symptom score showed significant im-
provements over control throughout the treatment period
(Fig. 3).
QoL significantly improved in patients treated with
omalizumab compared with control, with significant im-
provements seen in all individual domains and overall score
at 52 weeks (Table 3). A significantly greater proportion of
the omalizumab group achieved a clinically meaningful
(0.5-point) improvement from baseline in Mini-AQLQ over-
all score (76.5 vs. 41.7%, P < 0.001) at 52 weeks compared
with control. Similarly, a significantly greater proportion of
omalizumab-treated patients achieved a moderate (1.0-
point) improvement (55.1 vs. 25.0%, PZ 0.003) or large
(1.5-point) improvement in overall score (45.9 vs. 13.9%,
P < 0.001) at 52 weeks compared with control.
Responder identification (using Mini-AQLQ) and
outcomes
Data were available for 102 omalizumab-treated patients in
the Mini-AQLQ-assessed responder analysis. In total, 71/102
omalizumab-treated patients (70%) were classified as re-
sponders (0.5-point improvement in Mini-AQLQ overall
score at 27 weeks). It is also worth noting that 56 (54%)
achieved a moderate (1.0-point) improvement and 39
(38%) had a large (1.5-point) improvement. The baseline
Table 2 Use of systemic corticosteroids, antibiotics, medical resource utilization and absenteeism due to asthma
Omalizumab
(nZ 115)
Omalizumab
responders
(nZ 71)
Control
(nZ 49)
Use of systemic corticosteroids, n (%) 69 (64.5) 45 (64.3) 32 (80.0)
Median number of days of systemic corticosteroids use (range)a 34.0 (1e365) 36.0 (1e364) 43.0 (1e370)
Use of antibiotics, n (%) 42 (39.3) 28 (40.0) 22 (55.0)
Median number of days of antibiotics use (range)a 12.5 (2e108) 14.0 (3e93) 15.0 (3e56)
Unscheduled physician visits, n (%) 43 (40.2) 28 (40.0) 21 (52.5)
Median number of days with unscheduled physician visits (range)a 2.0 (1e12) 2.0 (1e12) 3.0 (1e19)
ER visits, n (%) 18 (16.8) 9 (12.9) 10 (25.0)
Median number of days with ER visits (range)a 1.0 (1e46) 1.0 (1e4) 1.5 (1e11)
Hospitalizations, n (%) 12 (11.2) 6 (8.6) 5 (12.5)
Median number of days of hospitalization (range)a 8.0 (1e53) 13.0 (1e45) 11.0 (2e21)
Absenteeism, n (%)b 56 (52.3) 40 (57.1) 27 (67.5)
Median number of days of absenteeism (range)a 15.5 (1e365) 15.5 (1e257) 46.0 (3e186)
a For patients experiencing this outcome.
b Or significantly reduced performance in non-working patients.
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treated responders and non-responders were similar (data
not shown).
In Mini-AQLQ-assessed responders, the annual exacerba-
tion rate (1.12) was significantly reduced by 64% compared
with control (rate ratio [95% CI]: 0.365 [0.244, 0.546];
P < 0.001, Fig. 1). The annual ADRI rate (4.71) was signifi-
cantly reduced by 50% compared with control (rate ratio
[95% CI]: 0.505 [0.310, 0.821]; P < 0.01). The individual
events that comprised ADRIs during the study in the Mini-
AQLQ-assessed responder group are summarized in Table
2. Responders had fewer occurrences and shorter durations
of all individual ADRI events compared with control (al-
though not statistically significant). However, compared
with the omalizumab group outcomes in responders were
broadly similar, with slight reductions seen in ER visits
and hospitalizations, and slight increases in duration of an-
tibiotic use, duration of hospitalization and absenteeism
(none of which were statistically significant).Figure 2 Effect of omalizumab on % predicted FEV1.
**P < 0.01 vs. control; ***P < 0.001 vs. control.Significant improvement in % predicted FEV1 was seen in
the Mini-AQLQ-assessed responders, compared with control
(Fig. 2). Absolute FEV1 was also further improved in re-
sponders compared with control. At baseline, absolute
mean [SD] FEV1 was 2.10 L [0.737] in responders and in-
creased to 2.29 L [0.80] at 1 year, representing a difference
of 360 mL compared with control. Mean [SD] baseline symp-
tom score was similar in responders and control (19.1 [9.80]
and 17.5 [9.44] respectively). Significant improvements
were seen in mean [SD] symptom score at 1 year compared
with control (11.0 [10.27] vs. 17.1 [10.65], P < 0.001), and
in change from baseline in symptom score throughout the
treatment period (Fig. 3).
At 52 weeks, 91.2% of the Mini-AQLQ-assessed re-
sponders identified at 26 weeks continued to show 0.5-
point improvement from baseline in Mini-AQLQ overall
score, 73.5% achieved a moderate (1.0-point) improve-
ment and 60.3% achieved a large (1.5-point) improve-
ment. The mean scores for individual domains and overallFigure 3 Effect of omalizumab on asthma symptom score.
*P < 0.05 vs. control; **P < 0.01 vs. control; ***P < 0.001 vs.
control.
Table 3 Change from baseline in Mini-AQLQ scores in the omalizumab and control groups
Domain,
mean
3 months 6 months 9 months 12 months
OMA
(nZ 104)
Control
(nZ 40)
OMA
(nZ 102)
Control
(nZ 39)
OMA
(nZ 102)
Control
(nZ 38)
OMA
(nZ 99)
Control
(nZ 37)
Symptoms 1.05* 0.48 1.20** 0.47 1.10** 0.39 1.31*** 0.19
Activities 1.16* 0.66 1.11** 0.45 1.09* 0.49 1.38*** 0.29
Environment 0.80 0.42 0.99* 0.44 1.03*** 0.11 1.19*** 0.03
Emotions 1.02 0.36 1.24* 0.50 1.32** 0.29 1.37*** 0.09
Overall 1.03* 0.50 1.14** 0.48 1.14*** 0.36 1.32*** 0.17
*P < 0.05; **P < 0.01; ***P < 0.001 vs. control. OMA, omalizumab.
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control groups are presented in Table 4.
Discussion
In this post-hoc subgroup analysis of data from a randomized
open-label study, adding omalizumab to high-dose ICS plus
a LABA significantly reduced clinically significant exacerba-
tion rates and ADRI rates. Lung function, asthma symptom
scores and QoL were also significantly improved in the
overall omalizumab-treated population of patients with
inadequately controlled severe persistent allergic asthma,
compared with control. Despite the relatively small patient
numbers, statistical significance was achieved for all
endpoints evaluated.
The magnitude of the benefits in the omalizumab-
treated population was similar to those seen in the original
study in patients with moderate-to-severe asthma.19 Most
importantly, these data also confirm the efficacy of omali-
zumab in a naturalistic setting in a patient population that
reflects the EU label for omalizumab (inadequately con-
trolled severe persistent allergic asthma despite high-dose
ICS plus a LABA) previously demonstrated in a randomized,
placebo-controlled study.18 Inadequate control of asthma
in the present study was clearly demonstrated by the im-
paired lung function, high symptoms scores and emergency
medical interventions prior to the study. More than 90% of
patients required an emergency room visit, almost 50% re-
quired hospitalization, and almost all patients required
short courses of OCS (approximately four per patient) in
the previous year. In addition, a remarkably high average
of around 50 school/work days had been lost due to asthma
in the previous year.Table 4 Change from baseline in Mini-AQLQ scores in the Mini-
Domain, mean 3 months 6 months
OMA-R
(nZ 70)
Control
(nZ 40)
OMA-R
(nZ 71)
Con
(nZ
Symptoms 1.5 0.48 1.79 0.4
Activities 1.53 0.66 1.65 0.4
Environment 1.21 0.42 1.64 0.4
Emotions 1.69 0.36 1.95 0.5
Overall 1.49 0.50 1.76 0.4
OMA-R, Mini-AQLQ-assessed omalizumab responder (0.5-point improThe clinical benefits of omalizumab in responders are of
particular importance as only patients who are judged by
a physician to have responded to therapy at 16 weeks
should continue to receive omalizumab (EU label), thereby
improving overall effectiveness, preventing unwarranted
drug exposure and improving cost-effectiveness.
An analysis by Bousquet et al. (2007)27 found that a phys-
ician’s overall assessment was the most useful and reliable
method of evaluating response to omalizumab therapy. In
their analysis, the physician’s overall assessment identified
61% of omalizumab-treated patients as responders who ex-
perienced marked reductions in the rate of clinically signif-
icant and severe exacerbations, along with a number of
additional measures of asthma control. As the physician’s
overall assessment was not an outcome measure in the cur-
rent analysis, we selected 0.5-point improvement in Mini-
AQLQ overall score to identify responders. This selection
was based on the findings of Bousquet et al. (2007),27 which
showed that broad measures such as improvements in QoL
are the most appropriate for evaluating response to omali-
zumab therapy. In their analysis, QoL also correlated very
strongly with physician and patient overall evaluation of
treatment effectiveness. Using a threshold of 0.5-point
improvement in the 32-item AQLQ showed similar (if some-
what less discriminatory) properties to the physician’s over-
all assessment.
As mentioned previously, response to therapy was
assessed at 27 weeks as this was the first assessment per-
formed after 16 weeks of therapy (the time specified for
evaluating response to omalizumab treatment in the EU la-
bel). In patients who were judged to have responded to
omalizumab (0.5-point improvement in Mini-AQLQ overall
score at 27 weeks) efficacy was further enhanced for allAQLQ-assessed omalizumab responders and control groups
9 months 12 months
trol
39)
OMA-R
(nZ 70)
Control
(nZ 38)
OMA-R
(nZ 68)
Control
(nZ 36)
7 1.59 0.39 1.73 0.19
5 1.54 0.49 1.84 0.29
4 1.65 0.11 1.65 0.03
0 1.97 0.29 1.99 0.09
8 1.67 0.36 1.81 0.17
vement in Mini-AQLQ).
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ADRI rates, lung function, and asthma symptoms.
Additionally, the improvement of 1.64 in change from
baseline in overall Mini-AQLQ score after 1 year compared
with control describes a high level of persistency of response.
Further reassurance that improvements in QoL following
treatment with omalizumab reflect a true pharmacological
effect rather than background disease variability is provided
by the much higher Mini-AQLQ responder persistency
(between 26 and 52 weeks) observed in the omalizumab
compared to control group. This confirms the persistency of
benefit after 52 weeks of omalizumab therapy.
The data analyzed from the original study19 were pre-
specified primary or secondary outcomes, and their use in
this post-hoc analysis of clinical outcomes in the severe
asthma subpopulation reflects the omalizumab EU label cri-
teria, which were introduced after the original study. The
post-hoc assessment of treatment efficacy in Mini-AQLQ-as-
sessed responders in our analysis also examines the response
assessment element of the EU label. This analysis required
the use of a surrogate assessment of response instead of
the validated physician’s overall assessment as described
by Bousquet et al.27 While a good correlation between the
AQLQ and the physician’s overall assessment has been de-
scribed,27 differences in response assessment criteria should
be borne in mind when evaluating the results in the re-
sponder group. As omalizumab responders represent a se-
lected subgroup of the omalizumab group rather than an
independent group, statistical comparison with the overall
omalizumab groupwas not possible. The comparison of oma-
lizumab responders with the control group should also be in-
terpreted with caution as this will tend to overestimate the
effect of omalizumab, although it serves to illustrate the ex-
pected real-world benefit of continuing therapy in only those
who respond to treatment as specified in the EU label, and
stopping therapy in those who do not show a response.
Although not as scientifically rigorous as randomized,
double-blind placebo-controlled (RDBPC) trials, it remains
important to understand how a therapy performs in a setting
more reflective of the real world, thereby gaining insight into
treatment benefits that might be expected for practicing
physicians. Real-world effectiveness data are meaningful,
but the limitations of such trial designs (e.g. the potential for
bias to be introduced by patients and investigators in the
assessment of outcomes and response assessment) should be
considered when interpreting open-label data, which should
be considered in the context of other RDBPC data.
Omalizumab RDBPC trials may have shown a particularly
large placebo effect34 due to the protocol requirements
and method of administration (physician observed therapy
every 2 or 4 weeks). This artificially increased contact
with healthcare providers beyond the usual standard of
care of patients may lead to an incremental placebo re-
sponse resulting from earlier detection and treatment of
loss of asthma control, increased compliance with asthma
medications and iatrogenic influences. The visit schedule
in this study, as distinct from the RDBPC INNOVATE study,18
may reflect real-world outcomes in a severe population.
Additionally, in the original study,19 all patients received
BSC as prescribed by the investigator. Wherever possible,
concomitant medication was to be minimized, but increas-
ing the dose of concomitant medications was permittedwhen required. Additional OCS and/or antibiotics were
also permitted for severe exacerbations. This approach to
concomitant medication reflects naturalistic practice. The
1-year duration of this study, compared with the 28-week
duration of INNOVATE, also facilitates the examination of
serious but relatively infrequent outcomes such as clinically
significant asthma exacerbations.
In conclusion, this subgroup analysis of data from a 1-
year, randomized, open-label study shows that adding
omalizumab to high-dose ICS plus a LABA significantly
improves asthma control. This is shown by reductions in
exacerbation and ADRI rates, improvements in lung func-
tion, asthma symptoms and QoL in patients with inade-
quately controlled severe persistent allergic asthma
compared with BSC alone. Patients classified as responders
show greater improvement in outcomes than the omalizu-
mab-treated group when compared with control, which
may illustrate the actual benefit of omalizumab in clinical
practice after response assessment at 16 weeks and con-
tinuing with therapy only in those patients who have re-
sponded to omalizumab as judged by the physician.
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